All Oncology News

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.

Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.

Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.

Dana-Farber Cancer Institute researchers are the recipients of the Outstanding Investigator Award from the NCI, part of the National Institutes of Health.

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

The FDA has called to add a class-wide boxed warning for CAR T-cell therapies to alert patients of the risk of developing secondary T-cell malignancies.

Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.

Neoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.

Abiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC.

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Sub-optimal integration of HRR mutation testing into clinical practice leads to a negative impact on treatment selection and outcomes in mCRPC.

Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.

Darolutamide plus docetaxel/ADT was associated with a lower rate of hospitalization compared with placebo in metastatic hormone-sensitive prostate cancer.

A program developed at Florida Cancer Specialists & Research Institute improves outcomes for patients prescribed selinexor for multiple myeloma.

William Pearse, MD, discusses how the FDA approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma has advanced BTK inhibitor treatment.

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.

KVA12123 demonstrated early signals of on-target activity and tolerability at all dose levels examined to date in patients with advanced solid tumors.

Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.

As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.

More than 125 Dana-Farber affiliated doctors have been included in Boston magazine's annual "Top Doctors" guide.

The field of hematology is experiencing significant advancements as promising new therapies for malignancies and GVHD continue to emerge.

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.

The phase 3 EVOKE-01 trial did not meet its primary end point of significantly improved OS with sacituzumab govitecan vs docetaxel in pretreated NSCLC.